Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer

Annals of Oncology

Volumn 14, Issue 2, 2003, Pages 242-247

  Bajetta, E ^a   Stani, S C ^a   De Candis, D ^a   Zaffaroni, N ^a   Zilembo, N ^a   Cortinovis, D ^a   Aglione, S ^a   Mariani, L ^a   Formisano, B ^a   Bidoli, P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carboplatin; Gemcitabine; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER CELL CULTURE; CANCER STAGING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IN VITRO STUDY; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0037294484     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg060     Document Type: Article

References (30)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
2. Schiller JH, Harrington D, Sandler A et al. A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: 1a (Abstr 2).
3. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
4. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6 (Suppl 6): 7-13.
5. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 1556-1562.
6. Van Moorsel CJA, Pinedo HM, Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer. Br J Cancer 1999; 80: 981-990.
7. Van Moorsel CJA, Pinedo HM, Veerman G et al. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 1999; 35: 808-814.
8. Gandara DR, Derick HML, Primo NL, Edelman MJ. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology 2000; 14: 26-30.
9. Edelman MJ, Gandara DR, Lau D et al. Sequential carboplatin/gemcitabine (C/G)→paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): an effective and well tolerated regimen. Proc Am Soc Clin Oncol 1999; 18: 502a (Abstr 1936).
10. Edelman MJ, Clark JI, Chansky K et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D). Proc Am Soc Clin Oncol 2001; 20: 314a (Abstr 1254).
11. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002; 21: 291a (Abstr 1162).
12. Rudd RM, Gower NH, James LE et al. Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 292a (Abstr 1164).
13. Thomas PA, Robinet G, Sylvie P et al. Randomized phase II study of carboplatin/gemcitabine versus cisplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) (GFPC 99-01 study). Proc Am Soc Clin Oncol 2002; 21: 336a (Abstr 1341).
14. Banks-Schegel SP, Gazdar AF, Harris CC. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res 1985; 45: 1187-1197.
15. Zaffaroni N, Silvestrini S, Orlandi L et al. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and resistant human ovarian cancer cells. Br J Cancer 1998; 77: 1378-1385.
16. Chou TC, Talaly P. Quantitative analysis of dose effect-relationship: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzym Regul 1984; 22: 27-55.
17. WHO. WHO Handbook for Reporting Results of Cancer Treatment, No. 48. Geneva, Switzerland: World Health Organization Offset Publication 1979.
18. Appendix A: grading of toxicity. In Wittes RE (ed): Manual of Oncology Therapeutics. Philadelphia, PA: JB Lippincott 1991; 445-448.
19. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II cancer trials. Biometrics 1985; 33: 429-435.
20. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
21. Sculier JP, Lafitte JJ, Lecomte J et al. A three-arm III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002; 13: 874-882.
22. Grigorescu AC, Draghici IN, Nitipir C et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 2002; 37: 9-14.
23. Carmichael J, Allerheiligen S, Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 1996; 23: 55-59.
24. Ng EW, Sandler AB, Einhorn LH. A phase II study of carboplatin plus gemcitabine in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17: 468a (Abstr 1801).
25. Carrato A, Garcia-Gomez J, Alberola V et al. Carboplatin in combination with gemcitabine in advanced non-small-cell lung cancer: comparison of trials using different schedules. Proc Am Soc Clin Oncol 1999; 18: 498a (Abstr 1922).
26. Iaffaioli RV, Tortoriello A, Facchini G et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999; 17: 921-926.
27. Gajra A, Melidi SA, Kirshner J et al. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer 2001; 32: 189-196.
28. Sheperd FA, Abratt R, Crinò L et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000; 30; 117-125.
29. Kroep JR, Peters GJ, Van Moorsel A et al. Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 1999; 10: 1503-1510.
30. Smith SL, Douglas KT. Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin. Biochem Biophys Res Commun 1989; 162: 715-723.